Data last refreshed November 8th, 2026Verified data can change without notice. Re-checked twice a month; next refresh due November 23rd, 2026.
Retatrutide suppliers: what each one publishes
Retatrutide is sold online by dozens of research-chemical sellers. People are buying it whatever anyone thinks about that, and the difference between sellers that publish a checkable purity report and sellers that only claim one is not visible from a product page. This table shows verified information for 15 of the most visible sellers.
Evo does not sell peptides and has no commercial relationship with anyone listed here. There are no affiliate links on this page and no seller paid to appear on it. Inclusion is not a recommendation — several of these sellers publish nothing you can verify.
Retatrutide seller comparison
We publish the raw data. Every figure in this table was read from the seller’s own page, with the source recorded — prices, certificate links, laboratory names, and how each score was calculated. Download the full capture (JSON) and check any row, or run your own analysis.
15 online retatrutide sellers with Evo Trust Score, average price per milligram, reference vial price, purity report, country and stock, captured November 8th, 2026.
A dash marks information we could not verify. Prices are the seller’s listed price for a single vial in their own currency, before any discount code. Vial sizes differ between sellers, so the per-milligram figure — the reference vial’s price divided by its size — is the only fair comparison — and 50 mg vials, the size easiest to compare, are sold by just 3 of the 15.
What each Evo Trust Score is made of
Every point below comes from something captured on the seller’s own site or from an independent testing platform. Nothing is an editorial impression.
Orbitrex Peptides
4.84.75 out of 5 stars
✓Report verifiable at the laboratory +1.5 Report published by Kovera Labs.
✓Batch-specific certificate published +1 A certificate is tied to a named lot.
✓Independently tested +1.5 24 retatrutide samples published by Finnrick, 91% passing.
✓Location disclosed +0.25 States United States.
·Established domain +0 Domain registered only 13 months ago.
✓Open catalog +0.5 Prices and stock are visible without an account.
Report hosted on Janoshik's verification portal; the record covers a 20 mg retatrutide lot.
The 10, 20 and 30 mg vials are all priced at the same rate per milligram; only the 60 mg is cheaper.
NeuroPept Labs
3.33.25 out of 5 stars
✓Report verifiable at the laboratory +1.5 Report published by Freedom Diagnostics.
✓Batch-specific certificate published +1 A certificate is tied to a named lot.
·Independently tested +0 No independent platform has published a retatrutide test for this seller.
✓Location disclosed +0.25 States United States.
·Established domain +0 Registration date not published in RDAP.
✓Open catalog +0.5 Prices and stock are visible without an account.
Listed sizes: 10 mg $84 · 20 mg $120 · 30 mg $185
Certificates are looked up on the laboratory's own site using the accession number supplied with the order. Lot 260217-12 reported 99.81% HPLC.
Lists a Tampa, Florida address. Each vial size is a separate listing, each sold in 1-, 2- and 3-vial variants; the prices above are the single-vial rate.
Paramount Peptides
2.52.5 out of 5 stars
·Report verifiable at the laboratory +0 Any certificate is hosted by the seller, so it cannot be checked at source.
✓Batch-specific certificate published +0.5 Certificates are collected on one page, not tied to the listed lot.
✓Independently tested +1 12 retatrutide samples published by Finnrick, 83% passing.
Independent testing:Finnrick has published 10 tests, with a 76% pass rate.
The listing requires an account, so no certificate is reachable publicly.
Sold as “GLP-1 R” at /product/reta/; the listing never prints the compound name. Prices and stock are behind a login. Lists a Charlotte, North Carolina address.
American Peptides
1.31.25 out of 5 stars
·Report verifiable at the laboratory +0 Any certificate is hosted by the seller, so it cannot be checked at source.
✓Batch-specific certificate published +0.5 Certificates are collected on one page, not tied to the listed lot.
·Independently tested +0 No independent platform has published a retatrutide test for this seller.
✓Location disclosed +0.25 States United States.
·Established domain +0 Registration date not published in RDAP.
✓Open catalog +0.5 Prices and stock are visible without an account.
A product certificate published as an image, with no lot number, so nothing ties it to the vial you receive. The PDF version linked until August 2026 now returns 404.
Each vial size is a separate listing.
How this page was built
Which sellers are listed. We measured who is actually visible for retatrutide rather than picking names. Twenty buying-intent Google queries — “buy retatrutide”, “retatrutide for sale”, “retatrutide 50mg” and similar — were pulled through a rank-tracking API, and every commerce domain in those results was scored by how highly and how often it appeared. That was combined with presence in Finnrick’s independent testing database, which surfaces sellers the community buys from that rank poorly on Google. The result is a visibility ranking, and visibility is not quality: some of the most visible sellers score worst below.
Where the numbers come from. Each seller’s own site was then read directly by a scraper — Shopify and WooCommerce product data where it exists, structured product markup otherwise — to capture vial sizes, prices, stock and any certificate links. Domain registration dates come from RDAP. Anything the scraper could not establish was checked by hand, and anything still unestablished was left blank. No figure on this page was estimated or inferred.
Where the independent testing comes from. The independent-testing points use Finnrick, which buys or receives samples that sellers did not control, has them laboratory-tested, and publishes the pass rates. We have no relationship with them and pay them nothing.
Their leaderboard answers a different question from this page. It ranks whoever has been submitted for testing, which skews heavily toward large business-to-business suppliers selling raw material by the gram — the best-rated vendors there sell at $0.57 to $1.20 per milligram, against several dollars on the retail sites in this table. It is not a ranking of the shops most people actually buy from, which is what this page is for. If you want laboratory evidence on a particular vendor, go to Finnrick; if you want to know what the shops you will actually find are publishing, that is this page.
What we removed. Six sites that rank well for retatrutide turned out not to sell it. Affiliate “best retatrutide vendor” guides recommended at least one seller whose catalog contains no retatrutide at all, which is a fair measure of how much those guides are worth:
peakformpeptides.com — Stopped carrying retatrutide. As of 2026-10-01 the listing 404s and the compound is absent from the product sitemap, the shop page, the GLP category and on-site search; cagrilintide and mazdutide are the only GLP-class products left. It ranked tenth, so the table is nineteen rows until the next quarterly re-rank.
primepeptides.co — Removed under our policy of excluding sellers that have received an explicit FDA warning letter naming this compound. FDA reviewed the site in October 2024 and cited its retatrutide product as an unapproved new drug: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-vitality-inc-dba-prime-peptides-695156-12102024
certapeptides.com — Ships from Romania. This list covers North American sellers, so it was removed despite scoring well — it published a Janoshik portal report and had Finnrick coverage.
redfoxpeptides.is — Dropped to hold the table at twenty; it scored lowest and had the least search visibility.
medicadepot.com — Dropped to hold the table at twenty; it scored lowest and published no certificate.
peptiq.io — Educational site — states plainly that it does not sell peptides or list vendors.
onyxbiolabs.com — Retatrutide is not in its 41-product catalog; it ranks on an article about the compound.
ascensionpeptides.com — Retatrutide is not in its 42-product catalog, despite affiliate guides recommending it as a retatrutide source.
biotechcompounds.com — Only a cagrilintide/retatrutide blend was listed, not retatrutide on its own.
seekpeptides.com — No retatrutide listing found; ranks on a dosage-calculator article.
simplepeptide.com — Catalog requires an account, so no listing, price or certificate could be captured.
peptide.partners — Removed under our policy of excluding sellers that have received an explicit FDA warning letter naming this compound. FDA’s August 24, 2026 letter names peptide.partners and “GLP-3 Reta (Retatrutide)” as an unapproved new drug: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026
What this page cannot tell you. A published certificate describes one lot at one moment. It does not tell you what is in the vial that arrives, whether the product was stored correctly, or whether the seller ships the batch they tested. Sterility and endotoxin testing are reported far less often than purity, and purity is not the same thing as safety. Prices and stock change constantly; this page is a snapshot, not a live feed.
Checking a report yourself
The strongest signal in the table costs nothing to check. Independent laboratories that test peptides — Janoshik is the most commonly cited — publish results at their own verification address, indexed by a report number. If a seller gives you a report number, you can open the laboratory’s site and read the same result the seller is quoting. A PDF hosted on the seller’s own domain cannot be checked that way, and an image of a certificate cannot be checked at all.
If you are working out concentration or syringe units from a vial, our retatrutide reconstitution calculator does that arithmetic and cites the published trial doses as protocols rather than recommendations. We keep a parallel table for BPC-157 sellers, scored on the same rubric.
Three details separate a useful certificate from a decorative one: it names the compound and the lot, the lot matches what is printed on the vial you received, and the date is recent enough to describe current stock rather than a batch sold a year ago. A report with no lot number is not evidence about your vial.
Questions people ask
Answered from the published trial data, the FDA’s own statements, and what we captured from the sellers themselves. Where the honest answer is that nobody knows yet, it says so.
How does retatrutide work?
Retatrutide is a single molecule that activates three receptors at once: GIP, GLP-1 and glucagon. That is what the shorthand “triple agonist” means, and it is what separates it from semaglutide, which acts on GLP-1 alone, and tirzepatide, which acts on two.
The first two receptors do broadly what they do in the existing drugs — slowing how quickly the stomach empties, acting on the appetite centres of the brain, and improving insulin response after eating. The third is the addition. Glucagon-receptor activation raises energy expenditure and acts on liver fat, which is the proposed reason the weight loss in trials ran higher than for the two-receptor drugs rather than simply lasting longer.
It is given as a once-weekly injection under the skin, and trials escalated the dose gradually over months because side effects track dose closely. Unlike some compounds sold in this market, retatrutide's mechanism is described in published, peer-reviewed trials rather than inferred from animal work — the uncertainty is about long-term outcomes, not about what it does.
Nobody can answer that completely yet, and anyone who tells you otherwise is guessing ahead of the evidence. Retatrutide has been through large trials that measured how well it works and what side effects it causes over 80 to 104 weeks, and those results are public. The trials that would establish long-term safety are still running, so the honest position is that the short- and medium-term side-effect profile is reasonably well described and the long-term picture is not.
Buying from a research-chemical seller adds a second risk that has nothing to do with the molecule itself: you do not know what is in the vial. Purity, how much active compound is actually in it, sterility and endotoxin content all vary between sellers and between batches. That is a separate question from whether retatrutide is safe, and it is the question this page exists to help with.
What side effects were reported in the trials?
In TRIUMPH-1, Eli Lilly's Phase 3 obesity trial of 2,339 participants over 80 weeks, the most common adverse events at the 12 mg dose were nausea (42.4% of participants, against 14.8% on placebo), diarrhoea (32.0% against 13.5%), constipation (26.1% against 10.9%) and vomiting (25.3% against 4.8%). Side effects were dose-related: the higher the dose, the more common they were.
Discontinuation tracked the same pattern. 11.3% of participants taking 12 mg stopped treatment because of adverse events, against 6.9% at 9 mg, 4.1% at 4 mg and 4.9% on placebo.
These figures describe supervised use of a pharmaceutical-grade product at known doses. They do not describe what happens with material of unknown purity or unknown fill accuracy, and they are not a list of everything that can go wrong.
No. Retatrutide is investigational and is not approved by the FDA for any use. Eli Lilly has said it intends to submit a Biologics License Application in the first quarter of 2027, so approval cannot arrive before then, and a submission is not an approval.
It also cannot lawfully be compounded. Retatrutide does not appear on the FDA's 503A or 503B bulk drug substance lists, has no USP monograph, is not a component of an approved drug and is not on the drug shortage list, which between them close every route a compounding pharmacy could use. Any pharmacy offering compounded retatrutide is operating outside that framework.
When will retatrutide be available on prescription?
Not before 2027, and possibly later. Lilly says it is completing the manufacturing data package required for a Biologics License Application and “plans to subsequently submit retatrutide in Q1 2027 for U.S. approval”. FDA review takes months after a filing, approval is not certain, and no launch date has been announced.
Anyone selling retatrutide today is selling it ahead of that process, not through it.
This is a description of how the market is regulated, not legal advice. Retatrutide is not a controlled substance. The sellers in the table above list it “for research use only” and “not for human consumption”, and that labelling is what lets it be sold without a prescription.
The label does not settle the question, and nobody involved treats it as literal. Research-use labelling functions as a shield across this whole market: the sellers know their customers are people, the customers know it, and the FDA's position is that intended use is established by the evidence rather than by what the vial says. The agency has issued warning letters on exactly that basis, and has said publicly that products sold this way “are of unknown quality and may be harmful to your health”. If your situation turns on the answer, ask a lawyer rather than a vendor.
The table above lists the 15 sellers with the most search visibility for retatrutide, what each one publishes, what it costs and whether it is in stock. Evo does not sell retatrutide, takes no commission, and does not recommend any seller on this page.
If you are going to buy anyway, the most useful single check is whether the purity report is published by the testing laboratory rather than hosted by the seller. Of the 15 sellers here, 3 clear that bar.
How much does retatrutide cost?
Verified reference-vial prices in US dollars ranged from $4.12 to $15.83 per milligram in the November 8th, 2026 capture, before discounts.
Price alone does not establish product quality. The table separates price from the evidence each seller publishes.
How much weight did people lose in the trials?
In the Phase 2 trial of 338 adults, participants on 12 mg lost an average of 24.2% of body weight at 48 weeks, against 2.1% on placebo.
In the Phase 3 TRIUMPH-1 trial of 2,339 participants at 80 weeks, average loss under the efficacy estimand was 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg, against 2.2% on placebo. Under the more conservative treatment-regimen estimand, which counts people who stopped treatment, the same doses gave 17.6%, 23.7% and 25.0%. A pre-specified extension to 104 weeks reached 30.3% at 12 mg.
These are averages from supervised trials using pharmaceutical-grade material at escalating doses, with the trial's own monitoring and support around them. They are trial protocols, not a recommendation, and individual results in a trial vary widely around an average.
Janoshik Analytical is an independent laboratory in Prague and the most widely used third-party tester in this market. It runs HPLC for purity and mass spectrometry for identity on samples sent to it, and publishes every result on its own verification portal, indexed by report number.
That last part is what makes it useful. A report you can look up on the laboratory's own site is one the seller could not have written or edited, so the number you are shown is the number the lab recorded. A PDF hosted on a seller's own domain carries no such guarantee, and a screenshot of a certificate carries none at all. The same reasoning applies to any laboratory that publishes results you can look up yourself.
Two limits are worth keeping in view. Janoshik is not ISO 17025 accredited, and a report describes the one sample the laboratory was sent — not necessarily the vial that arrives at your door.
How can I tell a certificate of analysis is genuine?
Check three things. The certificate should name a lot or batch number, and that number should match what is printed on the vial you received — a certificate with no lot number is not evidence about your material. The date should be recent enough to describe current stock rather than a batch sold a year ago. And the report should be verifiable somewhere other than the seller's own website, ideally at the testing laboratory itself.
Also read what the certificate actually covers. Most report purity by HPLC and identity by mass spectrometry. Fewer report fill accuracy, which is how much compound is really in the vial against what the label claims, and fewer still report sterility or endotoxin content. A 99% purity figure says nothing about any of those.
How should retatrutide be stored?
Sellers ship it as a lyophilised — freeze-dried — powder in a sealed vial, and their own labelling generally specifies storage below freezing, protected from light, with no cold chain required for shipping in that form. One seller in the table states −20°C on its listing; others state refrigeration. Follow what the seller of your specific product states, because formulations and excipients differ.
Storage guidance for reconstituted material is a different question and depends on the product, the diluent and how it was handled. If a seller does not state it, that is a gap in what they publish rather than something to guess at.